When was Upstream Medical Technologies founded?

Upstream Medical Technologies was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is Upstream Medical Technologies located?

Upstream Medical Technologies is headquartered in Dunedin, New Zealand. It is registered at Grant Thornton New Zealand Ltd, L3, 134 Oxford Terrace, Christchurch, 8011 , New Zealand.

Who is the current CEO of Upstream Medical Technologies?

Ruth Appleby of Upstream Medical Technologies.

Which legal entities is Upstream Medical Technologies associated with?

Upstream Medical Technologies is associated with UPSTREAM MEDICAL TECHNOLOGIES LIMITED.

How many employees does Upstream Medical Technologies have?

As of Aug 31, 2026, the latest employee count at Upstream Medical Technologies is 2.

Is Upstream Medical Technologies a funded company?

Upstream Medical Technologies is a funded company, having raised a total of $5.52M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 13, 2017.

When was the latest funding round of Upstream Medical Technologies?

Upstream Medical Technologies' latest funding was a $***** Series A round on Jan 14, 2018, with participation from 2 investors.

Where does Upstream Medical Technologies rank among its competitors?

Upstream Medical Technologies ranks 5th amongst 8 active competitors, of which 4 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was SphingoTec, which secured $5.46M in Aug, 2024.

Who are the top competitors of Upstream Medical Technologies?

Upstream Medical Technologies' top competitors include SphingoTec, BG Medicine and Critical Diagnostics. Among them, SphingoTec secured the most recent funding round in August, 2024.

Upstream Medical Technologies - 2026 Company Profile, Team, Funding & Competitors

Upstream Medical Technologies is a series A company based in Dunedin (New Zealand), founded in 2015. It operates as a Diagnostic device based on novel caridac biomarkers. Upstream Medical Technologies has raised $5.52M in funding from investors like European Investment Bank, Pacific Channel and Innovator Capital. The company has 8 active competitors, including 4 funded and 1 that has exited. Its top competitors include companies like SphingoTec, BG Medicine and Critical Diagnostics.

Company Details

Upstream Medical Technologies is a spin-out from the University of Otago, focused on developing definitive biomarker-based testing for the rapid diagnosis of heart diseases. The company is working towards the development of diagnostic device using their seven patented cardiac biomarkers. The company's The company's lead product BNP-sp will allow accurate diagnosis of unstable angina. Another product, Ghr-sp-Pne diagnoses heart failure in the presence of pneumonia.

Website: www.upstreamdx.com/
Email ID: *****@upstreamdx.com
Registered Address: Grant Thornton New Zealand Ltd, L3, 134 Oxford Terrace, Christchurch, 8011 , New Zealand

Key Metrics

Founded Year

2015

Location

Dunedin, New Zealand

Stage

Series A

Total Funding

$5.52M in 2 rounds

Latest Funding Round

Series A, Jan 14, 2018, $*****

Investors

European Investment Bank & 22 more

Ranked

5^th among 8 active competitors

Employee Count

2 as on Aug 31, 2026

Similar Companies

SphingoTec & 9 more

View Upstream Medical Technologies' full profile

Upstream Medical Technologies is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
UPSTREAM MEDICAL TECHNOLOGIES LIMITED CIN: 5792335 , New Zealand, Active	Aug 31, 2015	-	-

Upstream Medical Technologies has raised a total funding of $5.52M over 2 rounds. Its first funding round was on Nov 13, 2017. Its latest funding round was a Series A round on Jan 14, 2018 for $*****. 2 investors participated in its latest round. Upstream Medical Technologies has 7 institutional investors and 16 angel investors.

Here is the list of recent funding rounds of Upstream Medical Technologies:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 14, 2018	9843758	Series A	2743677	4091402	5132043	4254045
Nov 13, 2017	7932193	Seed	3805321	9984480	Pacific Channel	4003987

Access funding benchmarks and valuations. Sign up today!

View details of Upstream Medical Technologies's funding rounds and investors

Here are the details of Upstream Medical Technologies' key team members:

Ruth Appleby: CEO of Upstream Medical Technologies.

Upstream Medical Technologies' Board of Directors

Upstream Medical Technologies's board has 4 active members. Colin Dawson is part of team and David Christensen, Gary William Pace and Judith Lea Swain are independent board members.

Here is the list of Upstream Medical Technologies' board of directors:

Name	Type	Representing	Status	Duration
Colin Dawson	Team	-	Current	10y 10m
David Christensen	Independent board member	-	Current	11y 0m
tnhnovj	Independent board member	-	Current	7y 7m
ayluueu	Independent board member	-	Current	7y 5m

View details of Upstream Medical Technologies's Founder profiles and Board Members

Upstream Medical Technologies' employee count trend

Upstream Medical Technologies has 2 employees as of Aug 26. Here is Upstream Medical Technologies's employee count trend over the years:

Employee count trend for Upstream Medical Technologies

Uncover Upstream Medical Technologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Upstream Medical Technologies include SphingoTec, BG Medicine and Critical Diagnostics. Here is the list of Top 10 competitors of Upstream Medical Technologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	SphingoTec 2002, Hennigsdorf (Germany), Series C	Developer of biomarker-based diagnostic solutions for cancer, cardiovascular, and other diseases	$36.1M	Brandenburg Capital, Wellington Partners Venture Capital ... & 16 others	44/100
2nd	BG Medicine 2000, Waltham (United States), Public	Diagnostic tests for cardiovascular disorders.	$42.6M	Gilde Healthcare, General Electric & 3 others	42/100
3rd	Critical Diagnostics 2004, San Diego (United States), Series A	Developer of biomarkers-based tests for cardiovascular diseases diagnostics	$11.1M	Carrot Capital	38/100
4th	Pronota 2004, Ghent (Belgium), Acqui-Hired	Provider of diagnostics for heart failure, pre-eclampsia, and sepsis	$34.7M	VIB, Life Sciences Partners & 8 others	30/100
5th	Upstream Medical Technologies 2015, Dunedin (New Zealand), Series A	Diagnostic device based on novel caridac biomarkers	$5.52M	European Investment Bank, New Zealand Growth Capital Partners ... & 21 others	30/100
6th	Shape Medical Systems 2004, Saint Paul (United States), Series A	Innovative cardiopulmonary exercise testing solutions for streamlined diagnosis and therapy optimization	$8.32M	HHS	26/100
7th	CorPatch 2016, Svendborg (Denmark), Unfunded	Provider of the medical device to manage cardiac arrest	-	-	25/100
8th	Mirnext 2012, Amsterdam (Netherlands), Deadpooled	Provider of miRNA biomarker-based diagnostics for cardiovascular disease	-	Brightlands Venture Partners, Limburg Ventures ... & 1 others	20/100
9th	BioUniversa 2009, Montoro (Italy), Deadpooled	Developer of diagnostic biomarkers	-	Indaco Venture Partners, Vertis SGR	20/100
10th	Hf-ai-survival 2023, Unfunded	AI system developer for survival assessment in heart failure and renal dysfunction	-	-	16/100